Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Lymphoma 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1Ataxia Telangiectasia 1

Interventions

Cisplatin 57Radiotherapy 35Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 24Radiation 21Carboplatin 19pembrolizumab 18Specimen Handling 16Platinum 14Cetuximab 141,2-diaminocyclohexaneplatinum II citrate 14Surveys and Questionnaires 13Paclitaxel 13Biopsy 11Surgical Procedures, Operative 10Fluorouracil 10Docetaxel 9Taxes 8Nivolumab 8Drug Therapy 8Chemoradiotherapy 8durvalumab 7Fluorodeoxyglucose F18 7Observation 6Blood Specimen Collection 6fludarabine 5X-Rays 5Immunohistochemistry 5Cyclophosphamide 5aldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oropharyngeal Neoplasms × BAY 1895344 × Clear all
NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡